Taxane based chemotherapy drugs

What Are Taxane Chemo Drugs? Taxanes are a class of chemotherapy drugs used to treat numerous cancers, including breast, lung, stomach, prostate, ovarian, and pancreatic cancer. Taxanes inhibit cancer cell growth by disrupting the cell division process. Docetaxel, a drug marketed under the name Taxotere, is a taxane chemotherapy drug.

by A Shimomura 2024Meanwhile, perioperative anti-tumor drugs, especially anthracycline and taxane-based chemotherapy regimens, have been established to treat

Chemotherapy. Chemotherapy uses drugs to kill cancer cells. Most women with ovarian cancer receive a platinum-based drug and a taxane as first-line treatment.

In the comparison between taxane-based chemotherapy and platinum-based chemotherapy, taxane-based chemotherapy trended toward a slight benefit over the platinum-based chemotherapy, but without statistical significance (HR = 0.92, 95% CI 0.73 1.16, p = 0.47, I 2 = 0%). We also performed a subgroup analysis between the study types.

Taxotere (chemical name: Docetaxel) is a taxane chemotherapy drug. Taxanes interfere with the ability of cancer cells to divide.

Taxane-based chemotherapy is the conventional treatment for breast cancer and can significantly improve progression-free survival and overall survival of patients. [16,17] Taxane-based chemotherapy, especially docetaxel, results in fluid retention in extremities because of the increase of the extracellular fluid.

Abraxane (chemical name: albumin-bound or nab-paclitaxel) is a taxane chemotherapy drug. Taxanes are powerful chemotherapy medicines that

Also, the addition of trastuzumab to taxane-based chemotherapy increases the efficicacy of taxane-based regimens in women with stage 4 HER2-positive breast cancers. The schedule of administration of drugs, particularly with paclitaxel, appears to have an impact on efficacy.

Chemotherapy-induced peripheral neuropathy (CIPN) is most commonly associated with platinum-based drugs, taxanes, and vinca alkaloids. This prospective study from a single center in Kosovo aimed to evaluate CIPN in 120 patients receiving 4 6 cycles of platinum-based and taxane-based chemotherapy.